𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Benefit-Risk Assessment of the TNF-Antagonists Adalimumab and Certolizumab Pegol for Maintenance Treatment of Crohn's Disease

✍ Scribed by Colombel, Jean-Frederic ;Panaccione, Remo ;Robinson, Anne ;Thakkar, Roopal ;Huang, Bidan ;Pollack, Paul F.


Book ID
122307213
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
149 KB
Volume
140
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Certolizumab Pegol for the Treatment of
✍ Sandborn, William J.; Feagan, Brian G.; Stoinov, Simeon; Honiball, Pieter J.; Ru πŸ“‚ Article πŸ“… 2007 πŸ› Massachusetts Medical Society 🌐 English βš– 224 KB